Reports
Sale
Global Cell and Gene Therapy Market Size, Share, Trends: By Therapy Type: Cell Therapy Types, Gene Therapy Types; By Type: Cell Type, Gene Type; By Delivery Mode: In Vivo, Ex Vivo; By Vector Type: Viral Vector, Non-viral Techniques; By Therapeutic Area: Oncology, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Cell and Gene Therapy Market Size
The global cell and gene therapy market was valued at USD 17.4 billion in 2023, driven by robust regulatory support and growth in clinical trials for cell and gene therapies across the globe. The market size is anticipated to grow at a CAGR of 23.17% during the forecast period of 2024-2032 to achieve a value of USD 113.53 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cell and Gene Therapy Market Outlook
- The rise in the number of clinical trials for cell and gene therapies and the presence of a favorable regulatory environment are some of the factors set to drive market growth in the forecast period.
- Increased venture capitalist investments and public funding to accelerate the development of cell and gene therapies are major market trends poised to propel innovation in this sector.
- The rising innovations in CRISPR and other gene-editing technologies are anticipated to fuel the market share for cell and gene therapies.
Cell and Gene Therapy Market Overview
Cell therapy works on the principle of alteration, implantation, or restoration of cells or by extrapolating cells to carry the treatment through the body. In cell therapy, cells are modified outside the body, that is, in ex-vivo conditions, and then injected into the patient. On the other hand, gene therapy works by incorporating, deactivating, or displacing the genes into cells, which can occur both inside (in vivo) and outside (ex vivo) of the body. In the healthcare sector, some of the major treatments and curative remedies are developed using cell and gene modifications. Cell and gene therapy works by modifying the genes in particular cells and injecting them into the body. The essential resemblance between cell and gene therapy is the ability to mitigate the underlying cause of genetic disorders. There are enormous cell and gene therapies based on the origin or destination as per the treatment requirements.
The cell and gene therapy market is characterized by a strong pipeline activity indicated by a considerable increase in the number of clinical trials. The rising innovations in CRISPR and other gene-editing technologies are anticipated to fuel the market share. The emerging cell and gene therapies seem promising in commercial aspects. Key market leaders will be the gene therapy companies that will provide fast and effective treatment for debilitating diseases. Gene therapies developed by small, medium, and big biotech and pharmaceutical companies also tend to attract the attention of investors, which is likely to stimulate growth and innovation in the market.
Cell and Gene Therapy Market Growth Drivers
Robust Regulatory Support to Affect the Market Landscape Significantly
According to the Food and Drug Administration’s estimation, around 10 to 20 new cell and gene therapies are anticipated to be approved by 2025. In June 2023, the U.S. Food and Drug Administration approved the first gene therapy called Elevidys. It is intended for the treatment of pediatric patients aged 4 through 5 years who are suffering from Duchenne muscular dystrophy (DMD) and have confirmed mutations in the DMD gene. This therapy can be used for patients who do not have any pre-existing medical conditions that prevent treatment with this therapy. The rise in such regulatory approvals is anticipated to contribute significantly to the cell and gene therapy market share.
Along with Elevidys, the U.S. FDA has given approval to a total of 6 cell and gene therapies including Vyjuvek, ARCT-154, and Qalsody among other therapies. Besides supportive regulatory frameworks, advanced technologies and better healthcare infrastructure facilities are the additional factors aiding in the development of this market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cell and Gene Therapy Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Improvements in Manufacturing and Scalability | The market share is positively influenced by the rising use of automation and standardization in manufacturing processes which helps in improving scalability and reducing costs of cell and gene therapies. Additionally, the increased adoption of closed-system manufacturing to mitigate safety risks and contamination is also poised to elevate the market value. |
| Advancements in CAR-T and Other Cell Therapies | One of the major market trends is the rising advancements in CAR-T cell therapies such as the increased focus on next-generation CAR-T cells that exhibit higher efficacy and safety profiles. For example, Yescarta® was cleared by the FDA as the first CAR-T cell therapy for initial treatment of relapsed or refractory large B-cell lymphoma (LBCL). In addition, the development of other cell therapies like stem cell-based therapies is likely to augment the cell and gene therapy market demand. |
| Increased Funding and Investments | The rising influx of substantial venture capital investments into biotechnology companies involved in cell and gene therapies is a major market trend projected to bolster market growth. Further, the increased public funding and grants for accelerating research and development in this field are also expected to aid market expansion. |
| Expansion of Allogeneic Therapies | The market is experiencing notable growth in allogeneic or donor-derived cell therapy. Such therapies are produced in large quantities and can be stored for off-the-shelf use. Thus, compared to autologous (patient-specific) therapies, allogeneic therapies can be manufactured at lower manufacturing costs and are likely to boost market demand. |
Cell and Gene Therapy Market Segmentation
Market Breakup by Therapy Type
- Cell Therapy Types
- Autologous Cell Therapy
- Allogenic Cell Therapy
- Gene Therapy Types
- Somatic Gene Therapy
- Germline Gene Therapy
Market Breakup by Type
- Cell Type
- Stem Cell
- Non-Stem Cell
- Gene Type
- Antigen
- Cytokine
- Tumor Suppressor
- Growth Factors
- Receptors
- Others
Market Breakup by Delivery Mode
- In Vivo
- Ex Vivo
Market Breakup by Vector Type
- Viral Vector
- Non-viral Techniques
Market Breakup by Therapeutic Area
- Oncology
- Cardiology Diseases
- Neurological Disorders
- Genetic Disorders
- Infectious Diseases
- Hematological Disorders
- Musculoskeletal Disorders
- Others
Market Breakup by End User
- Hospitals
- Cancer Care Centers
- Academic and Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Cell and Gene Therapy Market Share
Market Segmentation Based on Therapy Type is Anticipated to Witness Substantial Growth
Based on the therapy type, the market is broadly segmented into cell therapy types and gene therapy types. The cell therapy types segment is further divided into autologous cell therapy and allogenic cell therapy whereas the gene therapy types include somatic and germline gene therapy. The gene therapy segment holds a high market value owing to the increase in regulatory approvals of several gene therapies such as Zolgensma (onasemnogene abeparvovec-xioi) approved by the FDA to treat spinal muscular atrophy in pediatric patients. Further, the development of innovative gene-editing technologies, such as CRISPR, is likely to expand the applications of the segment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cell and Gene Therapy Market Analysis by Region
Based on regional analysis, North America is expected to dominate the market due to the presence of key market players in the region. The United States of America has witnessed a substantial increase in biopharmaceutical companies performing clinical trials in cell and gene therapy. More than 1000 companies worldwide have been working on the development of cell and gene therapies across the globe, out of which, more than 500 companies are based in the United States.
Leading Players in the Global Cell and Gene Therapy Market
The key features of the market report comprise clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Amgen Inc.
California-based Amgen Inc. is a multinational biopharmaceutical company and is known for its innovative human therapeutics for serious illnesses. The company heavily invests in next-generation technologies such as gene editing to expand its offerings in the field of cell and gene therapy.
Novartis AG
Swiss multinational pharmaceutical corporation Novartis AG is a prominent player in the market. One of its key products KYMRIAH (autologous T cell immunotherapy) is used for the treatment of B‑cell precursor acute lymphoblastic leukemia (ALL) in patients up to 25 years of age.
Pfizer Inc.
Biopharmaceutical giant Pfizer Inc. is actively involved in gene therapy research and development and significantly contributes to the cell and gene therapy market growth. The multinational pharmaceutical corporation leverages strategic partnerships to develop gene therapies for genetic diseases.
Bluebird Bio, Inc.
Headquartered in Massachusetts (United States), Bluebird Bio, Inc. is a standalone commercial gene therapy company. This biotech firm is known for developing gene therapies for severe genetic diseases.
Other key players in the market include Castle Creek Pharmaceutical Holdings, Bristol-Myers Squibb, Kite Pharma, Inc., Vericel Corporation Inc., Kolon TissueGene Inc., Vertex Pharmaceuticals, Inc., Spark Therapeutics, Inc., CORESTEM Inc., Biogen Inc., Dendreon Pharmaceuticals LLC, and JCR Pharmaceuticals Co. Ltd., among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy Type |
|
| Breakup by Type |
|
| Breakup by Delivery Mode |
|
| Breakup by Vector Type |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Cell and Gene Therapy Market Report
- What was the cell and gene therapy market value in 2023?
- What is the cell and gene therapy market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on therapy type?
- What is the market breakup based on type?
- What is the market segmentation by delivery mode?
- What is the market breakup by vector type?
- What is market segmentation based on the therapeutic area?
- Who are the major end users in the market?
- What are the major factors aiding the global cell and gene therapy market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of chronic diseases and genetic disorders affect the market landscape?
- What are the major global cell and gene therapy market trends?
- How does the rise in the geriatric population impact the market size?
- Which therapy type will dominate the market share?
- Which type is expected to have a high market value in the coming years?
- Which delivery mode will experience the highest demand in the market segment?
- Which vector type is poised to dominate the market segment?
- Which therapeutic area is expected to lead the market share in the forecast period?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the cell and gene therapy market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Read Our Top Selling Reports
Latin America Advanced Wound Care Market
Global Aortic Valve Replacement Devices Market
Global Acute Kidney Injury Treatment Market
Global JE (Japanese Encephalitis) Vaccine Market
North America Laboratory Informatics Market
Global Laboratory Information System Market
South Africa Orthopaedic Braces and Supports Market
Health Economics and Outcomes Research (HEOR) Market
Picture Archiving and Communication System (PACS) Market
Contract Development and Manufacturing Organization (CDMO) Market
Cell and Gene Therapy Report Snapshots
Cell and Gene Therapy Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell and Gene Therapy Market Overview
3.1 Global Cell and Gene Therapy Market Historical Value (2017-2023)
3.2 Global Cell and Gene Therapy Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Cell and Gene Therapy Market Landscape*
5.1 Global Cell and Gene Therapy: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Cell and Gene Therapy: Product Landscape
5.2.1 Analysis by Therapy Type
5.2.2 Analysis by Indication
6 Global Cell and Gene Therapy Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Cell and Gene Therapy Market Segmentation (2017-2032)
7.1 Global Cell and Gene Therapy Market (2017-2032) by Therapy Type
7.1.1 Market Overview
7.1.2 Cell Therapy Types
7.1.2.1 Autologous Cell Therapy
7.1.2.2 Allogenic Cell Therapy
7.1.3 Gene Therapy Types
7.1.3.1 Somatic Gene Therapy
7.1.3.2 Germline Gene Therapy
7.2 Global Cell and Gene Therapy Market (2017-2032) by Type
7.2.1 Market Overview
7.2.2 Cell Type
7.2.2.1 Stem Cell
7.2.2.2 Non-Stem Cell
7.2.3 Gene Type
7.2.3.1 Antigen
7.2.3.2 Cytokine
7.2.3.3 Tumor Suppressor
7.2.3.4 Growth Factors
7.2.3.5 Receptors
7.2.3.6 Others
7.3 Global Cell and Gene Therapy Market (2017-2032) by Delivery Mode
7.3.1 Market Overview
7.3.2 In Vivo
7.3.3 Ex Vivo
7.4 Global Cell and Gene Therapy Market (2017-2032) by Vector Type
7.4.1 Market Overview
7.4.2 Viral Vector
7.4.3 Non-viral Techniques
7.5 Global Cell and Gene Therapy Market (2017-2032) by Therapeutic Area
7.5.1 Market Overview
7.5.2 Oncology
7.5.3 Cardiovascular Diseases
7.5.4 Neurological Disorders
7.5.5 Genetic Disorders
7.5.6 Infectious Diseases
7.5.7 Hematological Disorders
7.5.8 Musculoskeletal Disorders
7.5.9 Others
7.6 Global Cell and Gene Therapy Market (2017-2032) by End User
7.6.1 Market Overview
7.6.2 Hospitals
7.6.3 Cancer Care Centers
7.6.4 Academic and Research Institutes
7.6.5 Others
7.7 Global Cell and Gene Therapy Market (2017-2032) by Region
7.7.1 Market Overview
7.7.2 North America
7.7.3 Europe
7.7.4 Asia Pacific
7.7.5 Latin America
7.7.6 Middle East and Africa
8 North America Global Cell and Gene Therapy Market (2017-2032)
8.1 North America Cell and Gene Therapy Market (2017-2032) by Therapy Type
8.1.1 Market Overview
8.1.2 Cell Therapy Types
8.1.2.1 Autologous Cell Therapy
8.1.2.2 Allogenic Cell Therapy
8.1.3 Gene Therapy Types
8.1.3.1 Somatic Gene Therapy
8.1.3.2 Germline Gene Therapy
8.2 North America Cell and Gene Therapy Market (2017-2032) by Type
8.2.1 Market Overview
8.2.2 Cell Type
8.2.2.1 Stem Cell
8.2.2.2 Non-Stem Cell
8.2.3 Gene Type
8.2.3.1 Antigen
8.2.3.2 Cytokine
8.2.3.3 Tumor Suppressor
8.2.3.4 Growth Factors
8.2.3.5 Receptors
8.2.3.6 Others
8.3 North America Cell and Gene Therapy Market (2017-2032) by Delivery Mode
8.3.1 Market Overview
8.3.2 In Vivo
8.3.3 Ex Vivo
8.4 North America Cell and Gene Therapy Market (2017-2032) by Vector Type
8.4.1 Market Overview
8.4.2 Viral Vector
8.4.3 Non-viral Techniques
8.5 North America Cell and Gene Therapy Market (2017-2032) by Indication
8.5.1 Market Overview
8.5.2 Oncology
8.5.3 Cardiovascular Diseases
8.5.4 Neurological Disorders
8.5.5 Genetic Disorders
8.5.6 Infectious Diseases
8.5.7 Hematological Disorders
8.5.8 Musculoskeletal Disorders
8.5.9 Others
8.6 North America Cell and Gene Therapy Market (2017-2032) by End User
8.6.1 Market Overview
8.6.2 Hospitals
8.6.3 Cancer Care Centers
8.6.4 Academic and Research Institutes
8.6.5 Others
8.7 North America Global Cell and Gene Therapy Market (2017-2032) by Country
8.7.1 United States of America
8.7.2 Canada
9 Europe Global Cell and Gene Therapy Market (2017-2032)
9.1 Europe Cell and Gene Therapy Market (2017-2032) by Therapy Type
9.1.1 Market Overview
9.1.2 Cell Therapy Types
9.1.2.1 Autologous Cell Therapy
9.1.2.2 Allogenic Cell Therapy
9.1.3 Gene Therapy Types
9.1.3.1 Somatic Gene Therapy
9.1.3.2 Germline Gene Therapy
9.2 Europe Cell and Gene Therapy Market (2017-2032) by Type
9.2.1 Market Overview
9.2.2 Cell Type
9.2.2.1 Stem Cell
9.2.2.2 Non-Stem Cell
9.2.3 Gene Type
9.2.3.1 Antigen
9.2.3.2 Cytokine
9.2.3.3 Tumor Suppressor
9.2.3.4 Growth Factors
9.2.3.5 Receptors
9.2.3.6 Others
9.3 Europe Cell and Gene Therapy Market (2017-2032) by Delivery Mode
9.3.1 Market Overview
9.3.2 In Vivo
9.3.3 Ex Vivo
9.4 Europe Cell and Gene Therapy Market (2017-2032) by Vector Type
9.4.1 Market Overview
9.4.2 Viral Vector
9.4.3 Non-viral Techniques
9.5 Europe Cell and Gene Therapy Market (2017-2032) by Indication
9.5.1 Market Overview
9.5.2 Oncology
9.5.3 Cardiovascular Diseases
9.5.4 Neurological Disorders
9.5.5 Genetic Disorders
9.5.6 Infectious Diseases
9.5.7 Hematological Disorders
9.5.8 Musculoskeletal Disorders
9.5.9 Others
9.6 Europe Cell and Gene Therapy Market (2017-2032) by End User
9.6.1 Hospitals
9.6.2 Cancer Care Centers
9.6.3 Academic and Research Institutes
9.6.4 Others
9.7 Europe Global Cell and Gene Therapy Market (2017-2032) by Country
9.7.1 United Kingdom
9.7.2 Germany
9.7.3 France
9.7.4 Italy
9.7.5 Others
10 Asia Pacific Global Cell and Gene Therapy Market (2017-2032)
10.1 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Therapy Type
10.1.1 Market Overview
10.1.2 Cell Therapy Types
10.1.2.1 Autologous Cell Therapy
10.1.2.2 Allogenic Cell Therapy
10.1.3 Gene Therapy Types
10.1.3.1 Somatic Gene Therapy
10.1.3.2 Germline Gene Therapy
10.2 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Type
10.2.1 Market Overview
10.2.2 Cell Type
10.2.2.1 Stem Cell
10.2.2.2 Non-Stem Cell
10.2.3 Gene Type
10.2.3.1 Antigen
10.2.3.2 Cytokine
10.2.3.3 Tumor Suppressor
10.2.3.4 Growth Factors
10.2.3.5 Receptors
10.2.3.6 Others
10.3 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Delivery Mode
10.3.1 Market Overview
10.3.2 In Vivo
10.3.3 Ex Vivo
10.4 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Vector Type
10.4.1 Market Overview
10.4.2 Viral Vector
10.4.3 Non-viral Techniques
10.5 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Indication
10.5.1 Market Overview
10.5.2 Oncology
10.5.3 Cardiovascular Diseases
10.5.4 Neurological Disorders
10.5.5 Genetic Disorders
10.5.6 Infectious Diseases
10.5.7 Hematological Disorders
10.5.8 Musculoskeletal Disorders
10.5.9 Others
10.6 Asia Pacific Cell and Gene Therapy Market (2017-2032) by End User
10.6.1 Hospitals
10.6.2 Cancer Care Centers
10.6.3 Academic and Research Institutes
10.6.4 Others
10.7 Asia Pacific Global Cell and Gene Therapy Market (2017-2032) by Country
10.7.1 China
10.7.2 Japan
10.7.3 India
10.7.4 ASEAN
10.7.5 Australia
10.7.6 Others
11 Latin America Global Cell and Gene Therapy Market (2017-2032)
11.1 Latin America Cell and Gene Therapy Market (2017-2032) by Therapy Type
11.1.1 Market Overview
11.1.2 Cell Therapy Types
11.1.2.1 Autologous Cell Therapy
11.1.2.2 Allogenic Cell Therapy
11.1.3 Gene Therapy Types
11.1.3.1 Somatic Gene Therapy
11.1.3.2 Germline Gene Therapy
11.2 Latin America Cell and Gene Therapy Market (2017-2032) by Type
11.2.1 Market Overview
11.2.2 Cell Type
11.2.2.1 Stem Cell
11.2.2.2 Non-Stem Cell
11.2.3 Gene Type
11.2.3.1 Antigen
11.2.3.2 Cytokine
11.2.3.3 Tumor Suppressor
11.2.3.4 Growth Factors
11.2.3.5 Receptors
11.2.3.6 Others
11.3 Latin America Cell and Gene Therapy Market (2017-2032) by Delivery Mode
11.3.1 Market Overview
11.3.2 In Vivo
11.3.3 Ex Vivo
11.4 Latin America Cell and Gene Therapy Market (2017-2032) by Vector Type
11.4.1 Market Overview
11.4.2 Viral Vector
11.4.3 Non-viral Techniques
11.5 Latin America Cell and Gene Therapy Market (2017-2032) by Indication
11.5.1 Market Overview
11.5.2 Oncology
11.5.3 Cardiovascular Diseases
11.5.4 Neurological Disorders
11.5.5 Genetic Disorders
11.5.6 Infectious Diseases
11.5.7 Hematological Disorders
11.5.8 Musculoskeletal Disorders
11.5.9 Others
11.6 Latin America Cell and Gene Therapy Market (2017-2032) by End User
11.6.1 Hospitals
11.6.2 Cancer Care Centers
11.6.3 Academic and Research Institutes
11.6.4 Others
11.7 Latin America Global Cell and Gene Therapy Market (2017-2032) by Country
11.7.1 Brazil
11.7.2 Argentina
11.7.3 Mexico
11.7.4 Others
12 Middle East and Africa Global Cell and Gene Therapy Market (2017-2032)
12.1 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Therapy Type
12.1.1 Market Overview
12.1.2 Cell Therapy Types
12.1.2.1 Autologous Cell Therapy
12.1.2.2 Allogenic Cell Therapy
12.1.3 Gene Therapy Types
12.1.3.1 Somatic Gene Therapy
12.1.3.2 Germline Gene Therapy
12.2 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Type
12.2.1 Market Overview
12.2.2 Cell Type
12.2.2.1 Stem Cell
12.2.2.2 Non-Stem Cell
12.2.3 Gene Type
12.2.3.1 Antigen
12.2.3.2 Cytokine
12.2.3.3 Tumor Suppressor
12.2.3.4 Growth Factors
12.2.3.5 Receptors
12.2.3.6 Others
12.3 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Delivery Mode
12.3.1 Market Overview
12.3.2 In Vivo
12.3.3 Ex Vivo
12.4 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Vector Type
12.4.1 Market Overview
12.4.2 Viral Vector
12.4.3 Non-viral Techniques
12.5 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Indication
12.5.1 Market Overview
12.5.2 Oncology
12.5.3 Cardiovascular Diseases
12.5.4 Neurological Disorders
12.5.5 Genetic Disorders
12.5.6 Infectious Diseases
12.5.7 Hematological Disorders
12.5.8 Musculoskeletal Disorders
12.5.9 Others
12.6 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by End User
12.6.1 Hospitals
12.6.2 Cancer Care Centers
12.6.3 Academic and Research Institutes
12.6.4 Others
12.7 Middle East and Africa Global Cell and Gene Therapy Market (2017-2032) by Country
12.7.1 Saudi Arabia
12.7.2 United Arab Emirates
12.7.3 Nigeria
12.7.4 South Africa
12.7.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Clinical Trial Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Grant Analysis
15.1 Analysis by Year
15.2 Analysis by Amount Awarded
15.3 Analysis by Issuing Authority
15.4 Analysis by Grant Product
15.5 Analysis by Funding Institute
15.6 Analysis by Departments
15.7 Analysis by Recipient Organization
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Strategic Initiatives
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Market Share Analysis, By Region (Top 5 Companies)
18.1.1 Market Share Analysis: Global
18.1.2 Market Share Analysis: North America
18.1.3 Market Share Analysis: Europe
18.1.4 Market Share Analysis: Asia Pacific
18.1.5 Market Share Analysis: Others
18.2 Amgen Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Company News and Developments
18.2.5 Certifications
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Company News and Developments
18.3.5 Certifications
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Company News and Developments
18.4.5 Certifications
18.5 Bluebird Bio, Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Company News and Developments
18.5.5 Certifications
18.6 Castle Creek Pharmaceutical Holdings
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Company News and Developments
18.6.5 Certifications
18.7 Bristol-Myers Squibb
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Company News and Developments
18.7.5 Certifications
18.8 Kite Pharma, Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Company News and Developments
18.8.5 Certifications
18.9 Vericel Corporation Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Company News and Developments
18.9.5 Certifications
18.10 Kolon TissueGene Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Company News and Developments
18.10.5 Certifications
18.11 Vertex Pharmaceuticals, Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Company News and Developments
18.11.5 Certifications
18.12 Spark Therapeutics, Inc.
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Company News and Developments
18.12.5 Certifications
18.13 CORESTEM Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Company News and Developments
18.13.5 Certifications
18.14 Biogen Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Company News and Developments
18.14.5 Certifications
18.15 Dendreon Pharmaceuticals LLC.
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Company News and Developments
18.15.5 Certifications
18.16 JCR Pharmaceuticals Co. Ltd.
18.16.1 Financial Analysis
18.16.2 Product Portfolio
18.16.3 Demographic Reach and Achievements
18.16.4 Company News and Developments
18.16.5 Certifications
19 Global Cell and Gene Therapy Market – Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER